• Trendlyne logo
  • Markets
  • Alerts
  • F&O
  • MF
  • Reports
  • Screeners
  • Subscribe
  • Superstars
  • Portfolio
  • Watchlist
  • Insider Trades
  • Results
  • Data Downloader
  • Events Calendar
  • What's New
  • Explore
  • FAQs
  • Widgets
More
    Search stocks
    IND USA
    IND
    IND
    IND
    USA
    • Stocks
    • Futures & Options
    • Mutual Funds
    • News
    • Fundamentals
    • Reports
    • Corporate Actions
    • Alerts
    • Shareholding
    logo
    GlaxoSmithKline Pharmaceuticals Ltd.
    17 Apr 2025
    2745.80
    1.80%
    Trend turns favourable for GlaxoSmithKline Pharma, key levels to track
    Business Standard
    GlaxoSmithKline Pharma stock has seen formation of 'Golden Cross' on the daily chart on Thursday; last time the stock saw a similar development, it rallied almost 117% over the next 14 months.
    Copy LinkShare onShare on Share on Share on
    GlaxoSmithKline Pharmaceuticals Ltd. is trading below its 30 day SMA of 2765.3
    logo
    FDC Ltd.
    16 Apr 2025
    461.35
    0.89%
    CDSCO halts manufacture, sale, distribution of 35 FDCs over safety concerns
    Business Standard
    The list of unapproved FDCs includes antidiabetics, antibiotics, painkillers, infertility medications and nutritional supplements
    Copy LinkShare onShare on Share on Share on
    Number of FII/FPI investors decreased from 121 to 113 in Jun 2025 qtr
    logo
    Sanofi Consumer Healthcare India Ltd.
    16 Apr 2025
    4797.60
    1.03%
    Dividend, rights issue: Sanofi Consumer, 4 others to remain in focus
    Business Standard
    Here is the complete list of companies whose shares will trade ex-date on April 17, 2025, along with their key corporate announcements, as per data available on the BSE
    Copy LinkShare onShare on Share on Share on
    Sanofi Consumer Healthcare India Ltd. is trading below all available SMAs
    logo
    AstraZeneca Pharma India Ltd.
    15 Apr 2025
    9331.00
    1.18%
    AstraZeneca India surrenders marketing approval of prostate cancer drug
    Business Standard
    AstraZeneca Pharma India Ltd on Tuesday said it has surrendered the marketing authorisation of prostate cancer treatment drug Olaparib (Lynparza) 100mg and 150mg in India citing commercial reasons. The company had received marketing authorisation for Olaparib film-coated tablets 100mg and 150mg (Lynparza) on November 17, 2023, AstraZeneca Pharma India said in a regulatory filing. It has now surrendered the marketing authorisation of the indication of Olaparib (Lynparza) 100mg and 150mg, the filing added. "...since the date of receipt of marketing authorisation for the said indications i.e. November 17, 2023, till date, we have never marketed the said indication in India," the company said, adding, "the discontinuation decision is only on the basis of commercial reasons and is not due to efficacy or safety reasons." The drug is indicated in combination with Abiraterone and Prednisone or Prednisolone for the treatment of adult patients with metastatic castration-resistant prostate ..
    Copy LinkShare onShare on Share on Share on
    Number of FII/FPI investors increased from 164 to 181 in Jun 2025 qtr.
    logo
    Ajanta Pharma Ltd.
    15 Apr 2025
    2401.80
    0.15%
    Ajanta Pharma Positioned For Steady Growth; Jefferies Initiates Coverage With 'Buy'
    Ajanta Pharma Positioned For Steady Growth; Jefferies Initiates Coverage With 'Buy'
    NDTV Profit
    In Asia and Africa, which contribute 45% of revenue, Ajanta's success is attributed to an on-ground presence and a tailored product portfolio, according to Jefferies.
    Copy LinkShare onShare on Share on Share on
    Ajanta Pharma Ltd. has an average target of 3051.67 from 6 brokers.
    logo
    Dr. Reddy's Laboratories Ltd.
    15 Apr 2025
    1248.10
    0.27%
    Dr. Reddy's Share Price Rises 3% As Firm Dismisses Report On Job Cuts
    Dr. Reddy's Share Price Rises 3% As Firm Dismisses Report On Job Cuts
    NDTV Profit
    The pharma major called a Business Standard report on senior-level exits and cost trimming factually incorrect'.
    Copy LinkShare onShare on Share on Share on
    Dr. Reddy's Laboratories Ltd. average weekly volume is high.
    Dr Reddy's Denies Plans To Implement 25% Workforce Cost Reduction
    NDTV Profit | 14 Apr 2025 1 more
    No workforce reduction: Dr. Reddy's
    Business Line | 14 Apr 2025
    logo
    Pfizer Ltd.
    14 Apr 2025
    5222.50
    1.39%
    Pfizer ends development of promising obesity pill after safety concerns
    Business Standard
    According to the company's latest statement, one patient experienced a potential liver injury that may have been caused by the drug
    Copy LinkShare onShare on Share on Share on
    Number of FII/FPI investors increased from 129 to 139 in Jun 2025 qtr.
    logo
    Sun Pharmaceutical Industries Ltd.
    13 Apr 2025
    1631.20
    -0.31%
    Stock downfall: The side effects are real, but Sun Pharma stays on its feet
    Business Standard
    Growth hormone kicks in as India's largest pharma firm's vital signs hold amid generic strain
    Copy LinkShare onShare on Share on Share on
    Sun Pharmaceutical I.. has an average target of 2050.25 from 8 brokers.
    logo
    Sun Pharmaceutical Industries Ltd.
    13 Apr 2025
    1631.20
    -0.31%
    Drug makers Glenmark, Sun Pharma, Zydus recall products in US
    Business Line
    Companies initiate Class-II recall, which happens when use of, or exposure to, a violative product may lead to temporary or medically reversible health consequences
    Copy LinkShare onShare on Share on Share on
    Motilal Oswal released a Buy report for Sun Pharmaceutical Industries Ltd. with a price target of 1960.0 on 23 Sep, 2025.
    Glenmark, Sun Pharma, Zydus Recall Products In US
    NDTV Profit | 13 Apr 2025
    logo
    Wockhardt Ltd.
    12 Apr 2025
    1460.00
    -2.20%
    US tariffs, if extended to Indian pharma industry, will be a challenge: Wockhardt's Huzaifa Khorakiwala
    Business Line
    Confident that its product, WCK-5222-ZENIC, which has given 97% success in phase-3 clinical trials, would save millions of lives annually
    Copy LinkShare onShare on Share on Share on
    Wockhardt Ltd. is trading below all available SMAs
    more
    loading
    Trendlyne Logo Trendlyne
    Stay ahead of the market
    Markets Today
    • Nifty 50 today
    • Sensex today
    • Latest Quarterly results
    • FII & DII data today
    Dashboard
    • Industry & Sector analysis
    • ETFs
    • Mutual Funds
    • Bullish & Bearish spread
    • Global Indices
    Tools
    • Compare stocks
    • Widgets
    • Data Downloader
    • Excel Connect
    IPOs
    • Dashboard (Mainboard & SME)
    • Upcoming IPOs
    • Recently Listed IPOs
    • Most Successful IPOs
    Upcoming IPOs
    • DSM Fresh Foods
    • Greenleaf Envirotech
    • NSB BPO Solutions
    Quick Links
    • Contact us
    • Blogs
    • FAQs
    Company
    • Privacy
    • Terms of Use
    • Disclaimer
    Trendlyne Products
    • Starfolio
    • SmartOptions
    • Trendlyne US Global
    Get Mobile App
    • Android
    • iOS

    Copyright © 2025 Giskard Datatech Pvt Ltd (RA SEBI Reg No: INH000022507)